Comparative analysis of short-term and long-term LL-37-induced rosacea-like mouse models: Histopathological features and inflammatory immune responses

Abstract

Background: It is well recognized that developing new animal models, refining the existing mouse models, and thoroughly characterizing their features are essential for gaining a deeper understanding of rosacea pathogenesis and for advancing therapeutic strategies in this direction. Accordingly, we aimed to characterize the pathological features of a long-term LL-37-induced mouse model of rosacea and to compare the disease manifestations and pathophysiological characteristics between short-term and long-term LL-37-induced models. A key focus was to investigate differential gene expression and the underlying mechanisms of immune system dysregulation in these models.

Methods: We comparatively assessed skin lesion manifestations, the extent of inflammatory infiltration, sebaceous gland alterations, fibrosis, and angiogenesis in both models. Assessments were performed using photographic documentation, hematoxylin–eosin (HE) staining, Van Gieson's (VG) staining, immunohistochemistry, and Western blotting. Furthermore, we employed RNA sequencing to analyze differential gene expression in mouse skin. The RNA sequencing data were validated using immunofluorescence staining and Western blotting, with a specific focus on gene variations and mechanisms related to immune system dysregulation.

Results: Mice subjected to long-term LL-37 induction developed rosacea-like pathological features, including angiogenesis, thickened skin tissue, and sebaceous gland hypertrophy. In the short-term LL-37-induced model, immune dysregulation primarily involved the innate immune response. However, long-term LL-37 induction resulted in significant activation of both innate and adaptive immune responses.

Conclusion: The long-term LL-37-induced mouse model offers a valuable animal model for the detailed investigation of the pathological mechanisms driving moderate-to-severe rosacea with prolonged disease duration. Importantly, this model provides a significant experimental foundation for exploring the potential role of immune system dysregulation in rosacea pathogenesis.

Keywords

immune system / inflammation / LL-37 / model / rosacea

References

[1] Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society expert committee. J Am Acad Dermatol. 2020; 82(6): 1501-1510.

[2] Zuuren EJV, Arents BWM, van der Linden MMD. Rosacea: new concepts in classification and treatment. Am J Clin Dermatol. 2021; 22(4): 457-465.

[3] Kang CN-Y, Shah M, Tan J. Rosacea: an update in diagnosis, classification and management. Skin Ther Lett. 2021; 26(4): 1-8.

[4] Tüzün Y, Wolf R, Kutlubay Z, Karakuş Ö, Engin B. Rosacea and rhinophyma. Clin Dermatol. 2014; 32(1): 35-46.

[5] Dultra M, Barros P, Ivanchuk A, Pegas JR. Electrosurgery in the treatment of pedunculated rhinophyma. Annales de Dermatologie et de Venereologie. 2024; 151(2): 103270.

[6] Geng RSQ, Bourkas AN, Mufti A, Sibbald RG. Rosacea: pathogenesis and therapeutic correlates. J Cutan Med Surg. 2024; 28(2): 178-189.

[7] Nalbant EK, İmren IG, Dolek GT. Internalized stigma and its relationship with quality of life and perceived health status in rosacea and acne vulgaris: a comparative cross-sectional study. Cureus. 2024; 16(5): e60731.

[8] Oussedik E, Bourcier M, Tan J. Psychosocial burden and other impacts of rosacea on patients' quality of life. Dermatol Clin. 2018; 36(2): 103-113.

[9] Rodrigues-Braz D, Zhao M, Yesilirmak N, Aractingi S, Behar-Cohen F, Bourges JL. Cutaneous and ocular rosacea: common and specific physiopathogenic mechanisms and study models. Mol Vis. 2021; 27: 323-353.

[10] Holmes AD, Spoendlin J, Chien AL, Baldwin H, Chang ALS. Evidence-based update on rosacea comorbidities and their common physiologic pathways. J Am Acad Dermatol. 2018; 78(1): 156-166.

[11] Bąbolewska E, Brzezińska-Błaszczyk E. Human-derived cathelicidin LL-37 directly activates mast cells to proinflammatory mediator synthesis and migratory response. Cell Immunol. 2015; 293(2): 67-73.

[12] Li J, Yuan X, Tang Y, et al. Hydroxychloroquine is a novel therapeutic approach for rosacea. Int Immunopharmacol. 2020; 79: 106178.

[13] Yamasaki K, di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007; 13(8): 975-980.

[14] Kang Y, Zhang C, He Y, et al. Thalidomide attenuates skin lesions and inflammation in rosacea-like mice induced by long-term exposure of LL-37. Drug Des Devel Ther. 2022; 16: 4127-4138.

[15] Zhang C, Kang Y, Zhang Z, et al. Long-term administration of LL-37 can induce irreversible rosacea-like lesion. Curr Issues Mol Biol. 2023; 45(4): 2703-2716.

[16] Gallo RL, Granstein RD, Kang S, et al. Standard classification and pathophysiology of rosacea: the 2017 update by the National Rosacea Society expert committee. J Am Acad Dermatol. 2018; 78(1): 148-155.

[17] Cribier B. Rosacea under the microscope: characteristic histological findings. J Eur Acad Dermatol Venereol. 2013; 27(11): 1336-1343.

[18] Chen C, Wang P, Zhang L, et al. Exploring the pathogenesis and mechanism-targeted treatments of rosacea: previous understanding and updates. Biomedicine. 2023; 11(8): 2153.

[19] Le Y, Zhang J, Lin Y, et al. S100A9 exacerbates the inflammation in rosacea through toll-like receptor 4/MyD88/NF-κB signaling pathway. J Invest Dermatol. 2024; 144: 1985-1993.

[20] Miller LS. Toll-like receptors in skin. Adv Dermatol. 2008; 24: 71-87.

[21] Casas C, Paul C, Lahfa M, et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012; 21(12): 906-910.

[22] Meylan E, Tschopp J, Karin M. Intracellular pattern recognition receptors in the host response. Nature. 2006; 442(7098): 39-44.

[23] Yoon S-H, Hwang I, Lee E, et al. Antimicrobial peptide LL-37 drives rosacea-like skin inflammation in an NLRP3-dependent manner. J Invest Dermatol. 2021; 141(12): 2885-2894.

[24] Olona A, Leishman S, Anand PK. The NLRP3 inflammasome: regulation by metabolic signals. Trends Immunol. 2022; 43(12): 978-989.

[25] Buhl T, Sulk M, Nowak P, et al. Molecular and morphological characterization of inflammatory infiltrate in rosacea reveals activation of Th1/Th17 pathways. J Invest Dermatol. 2015; 135(9): 2198-2208.

[26] Redfern RL, Reins RY, McDermott AM. Toll-like receptor activation modulates antimicrobial peptide expression by ocular surface cells. Exp Eye Res. 2011; 92(3): 209-220.

[27] Brown TT, Choi EYK, Thomas DG, Hristov AC, Chan MP. Comparative analysis of rosacea and cutaneous lupus erythematosus: histopathologic features, T-cell subsets, and plasmacytoid dendritic cells. J Am Acad Dermatol. 2014; 71(1): 100-107.

[28] Gazi U, Gureser AS, Oztekin A, et al. Skin-homing T-cell responses associated with Demodex infestation and rosacea. Parasite Immunol. 2019; 41(8): e12658.

[29] Raphael I, Nalawade S, Eagar TN, Forsthuber TG. T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine. 2015; 74(1): 5-17.

[30] Krohn IK, Kortekaas Krohn I, Aerts JL, et al. T-cell subsets in the skin and their role in inflammatory skin disorders. Allergy. 2022; 77(3): 827-842.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.